Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 808 results for "Ibrutinib"

IMBRUVICA(R) (ibrutinib) Combination with anti CD20 Antibody Shows Compelling Results in Heavily Pretreated Patients with CLL and Related Diseases

Ibrutinib Three Year Follow-up of Single-Agent and Combination...

/PRNewswire/ -- /NOT INTENDED FOR UK MEDIA/ Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology Three year follow-up data from the Phase 1b/2 ..., 1 month ago

17 images for Ibrutinib, 1 month ago
MedIndia, 1 month ago
Med India, 1 month ago
Capital Bay, 1 month ago
Scottrade, 1 month ago
I Stock Analyst, 1 month ago
American Journal of Hematology, 1 month ago
OncLive, 1 month ago
Chemotherapy Advisor, 2 months ago
Chemotherapy Advisor, 3 months ago

Move Over Ibrutinib? New Agent Shows Strong Results for CLL

MILAN — Response rates were robust in patients with refractory or relapsed chronic lymphocytic leukemia (CLL) who were treated with ABT-199/GDC-0199, an investigational selective inhibitor of B-cell lymphoma-2 proteins, in a phase1 study. In ...
 Medscape1 month ago Ibrutinib mejora la supervivencia en pacientes CLL y SLL: Resultados del estudio RESONATE  PR Newswire1 month ago Ibrutinib Improves Survival in CLL and SLL Patients: Results From the RESONATE Study  Individual.com1 month ago EHA 2014: Ibrutinib improves survival in CLL and SLL patients, RESONATE study shows  European Cancer Organisation1 month ago
Med India

Erratum: Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Ibrutinib Resistance in Chronic Lymphocytic Leukemia ( Correspondence, N Engl J Med 2014 ; 370 : 2352 - 2354 ) . In the list of authors (page 2354), Mr. Perez's first name should have been Alexendar, rather than Alijandro. The article ...
 New England Journal of Medicine4 weeks ago Ohio State University Wexner Medical Center: Mechanisms of ibrutinib resistance identified in chronic lymphocytic leukemia  NewsRX1 month ago Mechanisms of Ibrutinib Resistance Identified in the Treatment of Chronic Lymphocytic Leukemia  Med India1 month ago Identification of mechanisms of ibrutinib resistance in chronic lymphocytic leukemia  Medical News Today1 month ago

Ibrutinib Stands Center Stage in CLL

A Decade of Progress in CLL Hello. I am Prof. John Gribben, Chair of Medical Oncology at Barts Cancer Institute, St. Bartholomew's Hospital, Queen Mary University of London, in London, United Kingdom. Welcome to this edition of Medscape Oncology ...
 General Medicine eJournal3 weeks ago

Ibrutinib Improves Survival Compared with Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia

Summary In an international randomized , patients with relapsed or refractory (CLL) or (SLL) who were treated with ibrutinib (Imbruvica®) lived longer without their disease getting worse (progression-free survival) than patients who received ...
 National Cancer Institute3 weeks ago Orphan designation: Ibrutinib for the treatment of treatment of lymphoplasmacytic lymphoma, for the: Treatment of lymphoplasmacytic lymphoma  European Medicines Agency1 month ago Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia  New England Journal of Medicine1 month ago Ibrutinib superior to ofatumumab for relapsed, refractory CLL, SLL  Orthopedics Today1 month ago

Ibrutinib, Star in CLL, Subject to Lowly Drug Resistance

The targeted agent ibrutinib ( Imbruvica , Pharmacyclics) for the treatment of chronic lymphocytic leukemia (CLL) has taken the world of hematologic oncology by storm. The latest round of praise came at the recent meeting of the American Society ...
 General Medicine eJournal1 month ago ONLINE FIRST: CLL: Debating Transplant versus BCR-Inhibitors When Chemoimmunotherapy Fails  Oncology Times1 week ago Chemotherapy-Free Combo Is Tested in CLL  American Journal of Public Health2 weeks ago CLL: Age Called Determination in Choosing Frontline Therapy  Oncology Times1 month ago

Ibrutinib Results RESONATE in Refractory CLL

Bruce D. Cheson, MD: Hello. I am Bruce Cheson, Deputy Chief of Hematology/Oncology and Head of Hematology at Georgetown University Hospital and the Lombardi Comprehensive Cancer Center in Washington, DC. Welcome to this edition of Medscape Oncology ...
 General Medicine eJournal1 month ago
Capital Bay

Drug hailed as breakthrough in leukaemia treatment

Ibrutinib was developed with the assistance of scientists at the Royal College of Surgeons in Ireland An international trial of a new drug for the treatment of the most common form of leukaemia has found it increases survival rates and leads to ...
 RTE Online1 month ago New cancer drug Ibrutinib boosts survival rate to 90%  Capital Bay1 month ago Could this be the end of chemotherapy? New leukaemia drug boosts survival rate to 90% and could eventually replace invasive chemical treatment  Capital Bay1 month ago Clinical trials prove new leukaemia drug boosts survival rate to 90%  Irish Medical Times4 weeks ago

TG Therapeutics Inc's TG-1101 in combination with Ibrutinib demonstrates compelling clinical activity and safety profile in patients

TG Therapeutics Inc:Announces preliminary clinical results from its ongoing Phase 2 study of TG-1101 (ublituximab).The company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib (IMBRUVICA), the oral BTK inhibitor ...
 Reuters1 month ago TG Therapeutics' TG-1101 (Ublituximab) in Combination With Ibrutinib Demonstrates Compelling Clinical Activity and Safety Profile in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)  Vision Monday1 month ago TG Therapeutics, Inc.' TG-1101 (Ublituximab) In Combination With Ibrutinib Demonstrates Compelling Clinical Activity And Safety Profile In Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL) And Mantle Cell Lymphoma (MCL)  BioSpace1 month ago TG THERAPEUTICS' : TG-1101 (Ublituximab) in Combination With Ibrutinib Demonstrates Compelling Clinical Activity and Safety Profile in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)  4 Traders1 month ago

L'ibrutinib améliore la survie chez les patients LLC et LPL : résultats de l'étude RESONATE

MILAN Au nom des chercheurs de l'étude RESONATE, le Dr Hillmen présentera les résultats de l'essai de phase III chez des patients LLC et LPL. Les patients atteints de leucémie lymphode chronique (LLC) ou de lymphome à petits lymphocytes ...
 PR Newswire1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less